MiR-21 targets 15-PGDH and promotes cholangiocarcinoma growth

Molecular Cancer Research

Volumn 12, Issue 6, 2014, Pages 890-900

  Lu, Lu ^a   Byrnes, Kathleen ^a   Han, Chang ^a   Wang, Ying ^a   Wu, Tong ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; CYCLOOXYGENASE 2; MICRORNA 21; NICOTINAMIDE ADENINE DINUCLEOTIDE; PROSTAGLANDIN E2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT CARCINOMA; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL GROWTH; CLONOGENESIS; CONTROLLED STUDY; DRUG TARGETING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN SITU HYBRIDIZATION; IN VITRO STUDY; IN VIVO STUDY; LENTIVIRINAE; MALE; METABOLITE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; VIRAL GENE DELIVERY SYSTEM; XENOGRAFT;

EID: 84902657217     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-13-0419     Document Type: Article

References (26)

1. Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer 2010;10:181-93.
2. Wu T. Cyclooxygenase-2 in hepatocellular carcinoma. Cancer Treat Rev 2006;32:28-44. (Pubitemid 43159775)
3. Tai HH. Prostaglandin catabolic enzymes as tumor suppressors. Cancer Metastasis Rev 2011;30:409-17.
4. Backlund MG, Mann JR, Holla VR, Buchanan FG, Tai HH, Musiek ES, et al. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem 2005;280:3217-23. (Pubitemid 40223783)
5. Wolf I, O'Kelly J, Rubinek T, Tong M, Nguyen A, Lin BT, et al. 15- hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res 2006;66:7818-23. (Pubitemid 44289243)
6. Thiel A, Ganesan A, Mrena J, Junnila S, Nykänen A, Hemmes A, et al. 15-hydroxyprostaglandin dehydrogenase is down-regulated in gastric cancer. Clin Cancer Res 2009;15:4572-80.
7. Kaliberova LN, Kusmartsev SA, Krendelchtchikova V, Stockard CR, Grizzle WE, Buchsbaum DJ, et al. Experimental cancer therapy using restoration of NAD+-linked 15-hydroxyprostaglandin dehydrogenase expression. Mol Cancer Ther 2009;8:3130-9.
8. Backlund MG, Mann JR, Holla VR, Shi Q, Daikoku T, Dey SK, et al. Repression of 15-hydroxyprostaglandin dehydrogenase involves histone deacetylase 2 and snail in colorectal cancer. Cancer Res 2008;68:9331-7.
9. Myung SJ, Rerko RM, Yan M, Platzer P, Guda K, Dotson A, et al. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci U S A 2006;103:12098-102. (Pubitemid 44215817)
10. Tseng-Rogenski S, Gee J, Ignatoski KW, Kunju LP, Bucheit A, Kintner HJ, et al. Loss of 15-hydroxyprostaglandin dehydrogenase expression contributes to bladder cancer progression. Am J Pathol 2010; 176:1462-8.
11. Tatsuwaki H, Tanigawa T, Watanabe T, Machida H, Okazaki H, Yamagami H, et al. Reduction of 15-hydroxyprostaglandin dehydrogenase expression is an independent predictor of poor survival associated with enhanced cell proliferation in gastric adenocarcinoma. Cancer Sci 2010;101:550-8.
12. Wakimoto N, Wolf I, Yin D, O'Kelly J, Akagi T, Abramovitz L, et al. Nonsteroidal anti-in flammatory drugs suppress glioma via 15- hydroxyprostaglandin dehydrogenase. Cancer Res 2008;68:6978-86.
13. Wu T. Cyclooxygenase-2 and prostaglandin signaling in cholangiocarcinoma. Biochim Biophys Acta 2005;1755:135 -50.
14. Patel T. Cholangiocarcinoma -controversies and challenges. Nat Rev Gastroenterol Hepatol 2011;2011:189- 200.
15. Sirica AE. Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology 2005;41:5-15. (Pubitemid 40066375)
16. Endo K, Yoon BI, Pairojkul C, Demetris AJ, Sirica AE. ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology 2002;36:439-50. (Pubitemid 34810365)
17. Hayashi N, Yamamoto H, Hiraoka N, Dono K, Ito Y, Okami J, et al. Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm. Hepatology 2001;34:638-50. (Pubitemid 32927986)
18. Chariyalertsak S, Sirikulchayanonta V, Mayer D, Kopp-Schneider A, Fürstenberger G, Marks F, et al. Aberrant cyclooxygenase isozyme expression in human intrahepatic cholangiocarcinoma. Gut 2001;48:80-6. (Pubitemid 32042646)
19. Han C, Leng J, Demetris AJ, Wu T. Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest. Cancer Res 2004;64:1369- 76.
20. Wu T, Leng J, Han C, Demetris AJ. The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells. Mol Cancer Ther 2004;3:299- 307.
21. Mott JL. MicroRNAs involved in tumor suppressor and oncogene pathways: implications for hepatobiliary neoplasia. Hepatology 2009;50:630- 7.
22. Selaru FM, Olaru AV, Kan T, David S, Cheng Y, Mori Y, et al. MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology 2009;49:1595-601.
23. Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT, et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006;130:2113-29. (Pubitemid 43816961)
24. Ambros V. microRNAs: tiny regulators with great potential. Cell 2001;107:823- 6.
25. Loffler D, Brocke-Heidrich K, Pfeifer G, Stocsits C, Hackermüller J, Kretzschmar AK, et al. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of micro-RNA-21 through a highly conserved enhancer. Blood 2007;110:1330-3. (Pubitemid 47281433)
26. Davis BN, Hilyard AC, Lagna G, Hata A. SMAD proteins control DROSHA-mediated microRNA maturation. Nature 2008;454:56-61. (Pubitemid 351931982)